Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* Active IBS diagnosis by a gastroenterologist~* Generalized Anxiety Disorder diagnosed by DSM-IV TR criteria and the Mini International Neuropsychiatric Interview for the DSM-IV (Mini)~* No changes in any non study medication once starting the study~Exclusion Criteria:~* Current diagnoses of Major Depressive Disorder, Panic Disorder, Social Phobia, Post Traumatic Stress Disorder, Obsessive Compulsive Disorders, Eating Disorders, Somatoform Disorders, Drug or alcohol abuse or dependence, or severe personality disorder~* Lifetime history of any Bipolar Disorder or Psychotic Disorder~* Concurrent GI disorders falling outside of Rome III Functional GI disorders~* Pregnant women or sexually active female subjects not using medically acceptable method of contraception~* Current suicidal ideation~* Unstable medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): Two weeks of placebo run in followed by 12 weeks of Duloxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).